Charles River Laboratories International, Inc. $CRL Shares Sold by Lawson Kroeker Investment Management Inc. NE

Lawson Kroeker Investment Management Inc. NE cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.9% in the 2nd quarter, HoldingsChannel reports. The fund owned 50,473 shares of the medical research company’s stock after selling 5,518 shares during the period. Charles River Laboratories International accounts for approximately 1.4% of Lawson Kroeker Investment Management Inc. NE’s holdings, making the stock its 23rd largest holding. Lawson Kroeker Investment Management Inc. NE’s holdings in Charles River Laboratories International were worth $7,658,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRL. Vanguard Personalized Indexing Management LLC lifted its position in Charles River Laboratories International by 19.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 11,678 shares of the medical research company’s stock worth $1,772,000 after purchasing an additional 1,921 shares during the period. Johnson Investment Counsel Inc. lifted its holdings in shares of Charles River Laboratories International by 5.4% in the second quarter. Johnson Investment Counsel Inc. now owns 20,570 shares of the medical research company’s stock valued at $3,121,000 after buying an additional 1,045 shares during the period. Aberdeen Group plc boosted its stake in Charles River Laboratories International by 44.8% during the second quarter. Aberdeen Group plc now owns 5,127 shares of the medical research company’s stock valued at $778,000 after buying an additional 1,586 shares in the last quarter. Blue Trust Inc. grew its holdings in Charles River Laboratories International by 6.4% during the second quarter. Blue Trust Inc. now owns 2,562 shares of the medical research company’s stock worth $389,000 after acquiring an additional 155 shares during the period. Finally, Callan Family Office LLC bought a new stake in Charles River Laboratories International in the second quarter worth about $340,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 2.9%

NYSE CRL opened at $167.17 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $230.02. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The stock has a market cap of $8.23 billion, a price-to-earnings ratio of -125.69, a PEG ratio of 4.47 and a beta of 1.50. The firm’s 50 day moving average price is $159.23 and its two-hundred day moving average price is $147.55.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. During the same quarter in the prior year, the company earned $2.80 earnings per share. The company’s revenue for the quarter was up .6% on a year-over-year basis. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on CRL shares. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday. Evercore ISI increased their target price on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, October 3rd. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and lifted their price target for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. Barclays upgraded Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $165.00 to $195.00 in a research report on Thursday, October 2nd. Finally, Citigroup upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Eight analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $179.93.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares of the company’s stock, valued at $3,800,681.60. The trade was a 3.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).